Janssen Halts Clinical Trials of Darzalex with PD-1/PD-L1 Inhibitors Amid Concerns Over Safety, Effectiveness
Janssen has decided to discontinue a Phase 1 trial…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Trial Data Supports Darzalex Combo as Potentially Effective in Myeloma Patients Who Don’t Respond to Revlimid
A combination of Darzalex (daratumumab) plus Kyprolis (carfilzomib)…
Canadian Researchers Launch Study to Make Stem Cell Transplants Safer, More Efficient
Researchers in Canada are studying how to reduce the…
MS Therapy May Ease Painful Side Effect of Velcade Treatment in Myeloma Patients, Study Says
A multiple sclerosis (MS) treatment reduced a common…
Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018
Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is…
Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells
The University of Alabama at Birmingham (UAB)…
